PT4 is a compound used for the treatment of cutaneous leishmaniasis (CL); it exhibits effective anti-leishmanial activity against both L. amazonensis and L. braziliensis, with IC50 values of 125.18 μM and 233.18 μM, respectively; it reduces mitochondrial membrane potential and increases reactive oxygen species production, leading to parasite death; it also demonstrates potent in vivo anti-inflammatory activity.